I am excited about the new opportunities from becoming the Chief Operating Officer at Medelis. There are so many promising new developments in oncology such as immuno-oncology, personalized medicine and companion diagnostics.
Nashville, TN (PRWEB) June 11, 2015
Medelis, Inc., a specialty oncology CRO, today announced that David Browning has been promoted to the role of Chief Operating Officer.
“David Browning has a proven track record of not only delivering oncology studies on time and on budget, but also in exceeding client expectations by leveraging a proactive and partner-like approach,” said Larry Flanagan, Medelis’ CEO and co-founder. “His promotion is well-deserved.”
Browning joined Medelis in 2004 and has personally managed over 200 clinical trials, mostly in oncology including many in the emerging immuno-oncology field. Browning shared some of those immuno-oncology experiences last month in an educational webinar about how the irRC is changing immunotherapy treatments.
"I am excited about the new opportunities from becoming the Chief Operating Officer at Medelis. There are so many promising new developments in oncology such as immuno-oncology, personalized medicine and companion diagnostics,” said Browning. “It’s an honor to be able to contribute to sponsor’s successes, and more importantly, to the patients receiving the treatments.”
Browning will continue to oversee Medelis’ clinical operations in the U.S. and also work closely with Bill Taaffe, President of Medelis, in evaluating new study opportunities and sponsor’s clinical development plans.
Medelis is a specialty oncology CRO focused on phase I through phase III oncology trials in North America and Europe. Founded in 2003, Medelis provides sponsors with oncology expertise from drug development thought-leadership to a highly skilled clinical operations team, handling complex oncology trials in all indications including cutting-edge immunotherapy treatments.